NCT04576156 2025-12-04A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor TreatmentGeron CorporationPhase 3 Active not recruiting327 enrolled
NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts
NCT06468033 2025-08-13P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskPharmaEssentiaPhase 3 Recruiting150 enrolled
NCT01773187 2020-09-29Pacritinib Versus Best Available Therapy to Treat MyelofibrosisCTI BioPharmaPhase 3 Terminated327 enrolled 11 charts
NCT00952289 2018-03-12COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialIncyte CorporationPhase 3 Completed309 enrolled 18 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts